Zura Bio Investor Relations Material

Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative therapies for immune and inflammatory disorders. It leverages multi-asset immunology to create novel dual-pathway antibodies, including tibulizumab, ZB-168, and torudokimab, which are designed to address autoimmune diseases and other conditions with unmet medical needs. These therapies have completed early-phase studies and are advancing towards further clinical development. Zura Bio Limited is headquartered in Henderson, Nevada, and its shares are listed on NASDAQ.